Lipoxin A4 (
LXA4), as an endogenously produced
lipid mediator, promotes the resolution of
inflammation. Previously, we demonstrated that
LXA4 stimulated alveolar fluid clearance through alveolar
epithelial sodium channel gamma (ENaC-γ). In this study, we sought to investigate the mechanisms of
LXA4 in modulation of ENaC-γ in
lipopolysaccharide (LPS)-induced inflammatory
lung injury. miR-21 was upregulated during an LPS challenge and downregulated by
LXA4 administration in vivo and in vitro. Serum miR-21 concentration was also elevated in
acute respiratory distress syndrome patients as compared with healthy volunteers. LPS increased miR-21 expression by activation of
activator protein 1 (AP-1). In A549 cells, miR-21 upregulated phosphorylation of AKT activation via inhibition of
phosphatase and
tensin homolog (PTEN), and therefore reduced the expression of ENaC-γ. In contrast,
LXA4 reversed LPS-inhibited ENaC-γ expression through inhibition of
AP-1 and activation of PTEN. In addition, an miR-21 inhibitor mimicked the effects of
LXA4; overexpression of miR-21 abolished the protective effects of
LXA4. Finally, both AKT and ERK inhibitors (
LY294002 and
UO126) blocked effects of LPS on the depression of ENaC-γ. However,
LXA4 only inhibited LPS-induced phosphorylation of AKT. In summary,
LXA4 activates ENaC-γ in part via the miR-21/PTEN/AKT signaling pathway.